Immunological risk assessment: The key to individualized immunosuppression after kidney transplantation

Transplantation Reviews

Volumn 30, Issue 2, 2016, Pages 77-84

  Pratschke, Johann ^a   Dragun, Duska ^a   Hauser, Ingeborg A ^b   Horn, Sabine ^c   Mueller, Thomas F ^d   Schemmer, Peter ^e   Thaiss, Friedrich ^f  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; DELAYED GRAFT FUNCTION; ETHNICITY; GRAFT SURVIVAL; HLA MATCHING; HLA SYSTEM; HUMAN; IMMUNOGENICITY; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MEDICATION COMPLIANCE; OBESITY; ORGAN PRESERVATION; PREGNANCY; REVIEW; RISK ASSESSMENT; SENSITIZATION; VIRUS INFECTION; GRAFT REJECTION; HISTOCOMPATIBILITY TEST; PROCEDURES; RISK FACTOR;

IMMUNOSUPPRESSIVE AGENT;

DELAYED GRAFT FUNCTION; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; RISK ASSESSMENT; RISK FACTORS;

EID: 84960830734     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2016.02.002     Document Type: Review

References (111)

1. KDIGO Clinical practice guideline for the care of kidney transplant recipients. Am J Transpl 2009, 9(Suppl. 3):1-155.
2. Lebranchu Y., Baan C., Biancone L., et al. Pretransplant identification of acute rejection risk following kidney transplantation. Transpl Int 2014, 27:129-138.
3. Ekberg J., Ekberg H., Jespersen B., et al. An in-progress, open-label, multi-centre study (SAILOR) evaluating whether a steroid-free immunosuppressive protocol, based on ATG induction and a low tacrolimus dose, reduces the incidence of new onset diabetes after transplantation. Transplant Res 2014, 3:12.
4. Ejaz N.S., Shields A.R., Alloway R.R., et al. Randomized controlled pilot study of B cell-targeted induction therapy in HLA sensitized kidney transplant recipients. Am J Transplant 2013, 13:3142-3154.
5. Grafals M., Smith B., Murakami N., et al. Immunophenotyping and efficacy of low dose ATG in non-sensitized kidney recipients undergoing early steroid withdrawal: a randomized pilot study. PLoS One 2014, 9.
6. Hanaway M.J., Woodle E.S., Mulgaonkar S., et al. Alemtuzumab induction in renal transplantation. N Engl J Med 2011, 364:1909-1919.
7. Pilch N.A., Taber D.J., Moussa O., et al. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation. Ann Surg 2014, 259:888-893.
8. Van Gelder T., Tedesco Silva H., de Fijter J.W., et al. Renal transplant patients at high risk of acute rejection benefit from adequate exposure to mycophenolic acid. Transplantation 2010, 89:595-599.
9. United States Renal Data System 2014 annual data report Available at, [Accessed 9th October 2015]. http://www.usrds.org/adr.aspx.
10. Opelz G., Döhler B. Ceppellini lecture 2012: collateral damage from HLA mismatching in kidney transplantation. Tissue Antigens 2013, 82:235-242.
11. Kuo H.T., Sampaio M.S., Vincenti F., Bunnapradist S. Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the organ procurement and transplant network/united network for organ sharing (OPTN/UNOS) database. Am J Kidney Dis 2010, 56:1127-1139.
12. Meier-Kriesche H.U., Schold J.D., Srinivas T.R., Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004, 4:378-383.
13. McDonald S., Russ G., Campbell S., Chadban S. Kidney transplant rejection in Australia and New Zealand: relationships between rejection and graft outcome. Am J Transplant 2007, 7:1201-1208.
14. Opelz G., Döhler B. Collaborative Transplant Study Report. Influence of time of rejection on long-term graft survival in renal transplantation. Transplantation 2008, 85:661-666.
15. Dunn T.B., Noreen H., Gillingham K., et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant 2011, 11:2132-2143.
16. Sellarés J., de Freitas D.G., Mengel M., et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012, 12:388-399.
17. Willicombe M., Roufosse C., Brookes P., et al. Acute cellular rejection: impact of donor-specific antibodies and C4d. Transplantation 2014, 97:433-439.
18. Loupy A., Vernerey D., Tinel C., et al. Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts. J Am Soc Nephrol 2015, 26:1721-1731.
19. Wongsaroj P., Kahwaji J., Vo A., Jordan S.C. Modern approaches to incompatible kidney transplantation. World J Nephrol 2015, 4:354-362.
20. Jordan S.C., Choi J., Vo A. Kidney transplantation in highly sensitized patients. Br Med Bull 2015, 114:113-125.
21. Jordan S.C., Choi J., Vo A. Achieving incompatible transplantation through desensitization: current perspectives and future directions. Immunotherapy 2015, 7:377-398.
22. Okumi M., Toki D., Nozaki T., et al. ABO-incompatible living kidney transplants: evolution of outcomes and immunosuppressive management. Am J Transplant 2016, 16:886-896.
23. Böhmig G.A., Farkas A.M., Eskandary F., Wekerle T. Strategies to overcome the ABO barrier in kidney transplantation. Nat Rev Nephrol 2015, 11:732-747.
24. Kuo H.T., Huang E., Emami S., et al. Effects of antibody induction on transplant outcomes in human leukocyte antigen zero-mismatch deceased donor kidney recipients. Transplantation 2012, 93:493-502.
25. Brennan D.C., Daller J.A., Lake K.D., Cibrik D., Del Castillo D., Group Thymoglobulin Induction Study Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006, 355:1967-1977.
26. Nöel C., Abramowicz D., Durand D., et al. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol 2009, 20:1385-1392.
27. Vincenti F., Charpentier B., Vanrenterghem Y., et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010, 10:535-546.
28. Durrbach A., Pestana J.M., Pearson T., et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010, 10:547-557.
29. Tedesco-Silva H., Cibrik D., Johnston T., et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010, 10:1401-1413.
30. Langer R.M., Hené R., Vitko S., et al. Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation. Transplant Int 2012, 25:592-602.
31. Pascual J., Royuela A., Galeano C., Crespo M., Zamora J. Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review. Nephrol Dial Transplant 2012, 27:825-832.
32. Sureshkumar K.K., Thai N.L., Hussain S.M., Ko T.Y., Marcus R.J. Influence of induction modality on the outcome of deceased donor kidney transplant recipients discharged on steroid-free maintenance immunosuppression. Transplantation 2012, 93:799-805.
33. Tanriover B., Zhang S., MacConmara M., et al. Induction therapies in live donor kidney transplantation on tacrolimus and mycophenolate with or without steroid maintenance. Clin J Am Soc Nephrol 2015, 10:1041-1049.
34. Haynes R., Harden P., et al. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. Lancet 2014, 384:1684-1690. The 3C Study Collaborative Group.
35. Martins P.N., Tullius S.G., Markmann J.F. Immunosenescence and immune response in organ transplantation. Int Rev Immunol 2014, 33:162-173.
36. Tullius S.G., Tran H., Guleria I., Malek S.K., Tilney N.L., Milford E. The combination of donor and recipient age is critical in determining host immunoresponsiveness and renal transplant outcome. Ann Surg 2010, 252:662-674.
37. Tullius S.G., Milford E. Kidney allocation and the aging immune response. New Eng J Med 2011, 364:1369-1370.
38. Cole E., Johnston O., Rose C.L., Gill J.S. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 2008, 3:814-821.
39. Gore J.L., Pham P.T., Danovitch G.M., et al. Obesity and outcome following renal transplantation. Am J Transplant 2006, 6:357-363.
40. Øien C.M., Reisaeter A.V., Leivestad T., Dekker F.W., Line P.D., Os I. Living donor kidney transplantation: the effects of donor age and gender on short- and long-term outcomes. Transplantation 2007, 83:600-606.
41. Pallardó Mateu L.M., Sancho Calabuig A., Capdevila Plaza L., Franco Esteve A. Acute rejection and late renal transplant failure: risk factors and prognosis. Nephrol Dial Transplant 2004, 19:iii38-iii42. [Suppl.].
42. Quiroga I., McShane P., Koo D.D., et al. Major effects of delayed graft function and cold ischaemia time on renal allograft survival. Nephrol Dial Transplant 2006, 21:1689-1696.
43. Mota A., Figueiredo A., Cunha M.F., Bastos M., Pratas J., Furtado L. Risk factors for acute rejection in 806 cyclosporine-treated renal transplants: a multivariate analysis. Transplant Proc 2003, 35:1061-1063.
44. Narayanan M., Pankewycz O., El-Ghoroury M., et al. Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression. Transplantation 2013, 95:566-572.
45. Jacobson P.A., Oetting W.S., Brearley A.M., Investigators DeKAF, et al. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. Transplantation 2011, 91:300-308.
46. Schold J.D., Srinivas T.R., Braun W.E., Shoskes D.A., Nurko S., Poggio E.D. The relative risk of overall graft loss and acute rejection among African American renal transplant recipients is attenuated with advancing age. Clin Transplant 2011, 25:721-730.
47. Qiu J., Terasaki P.I., Waki K., Cai J., Gjertson D.W. HIV-positive renal recipients can achieve survival rates similar to those of HIV-negative patients. Transplantation 2006, 81:1658-1661.
48. Brown K.L., El-Amm J.M., Doshi M.D., et al. Intermediate-term outcomes of hepatitis C-positive compared with hepatitis C-negative deceased-donor renal allograft recipients. Am J Surg 2008, 195:298-302.
49. OPTN/SRTR annual data report 2013. Am J Transplant 2015, 15:4-13.
50. Ahmad N., Ahmed K., Khan M.S., et al. Living-unrelated donor renal transplantation: an alternative to living-related donor transplantation?. Ann R Coll Surg Engl 2008, 90:247-250.
51. Chkhotua A.B., Klein T., Shabtai E., et al. Kidney transplantation from living-unrelated donors: comparison of outcome with living-related and cadaveric transplants under current immunosuppressive protocols. Urology 2003, 62:1002-1006.
52. Saidi R.F., Elias N., Kawai T., et al. Outcome of kidney transplantation using expanded criteria donors and donation after cardiac death kidneys: realities and costs. Am J Transplant 2007, 12:2769-2774.
53. Diet C., Audard V., Roudot-Thoraval F., Matignon M., Lang P., Grimbert P. Immunological risk in recipients of kidney transplants from extended criteria donors. Nephrol Dial Transplant 2010, 25:2745-2753.
54. Aubert O., Kamar N., Vernerey D., et al. Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study. Br Med J 2015, 351:h3557.
55. Sánchez-Fructuoso A.I., Prats D., Marques M., et al. Does donor brain death influence acute vascular rejection in the kidney transplant?. Transplantation 2004, 76:142-146.
56. Chisholm M.A. Issues of adherence to immunosuppressant therapy after solid-organ transplantation. Drugs 2002, 62:567-575.
57. Greenstein S., Siegal B. Compliance and noncompliance in patients with a functioning renal transplant: a multicenter study. Transplantation 1998, 66:1718-1726.
58. Pinsky B.W., Takemoto S.K., Lentine K.L., Burroughs T.E., Schnitzler M.A., Salvalaggio P.R. Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression. Am J Transplant 2009, 9:2597-2606.
59. Dobbels F., Ruppar T., De Geest S., Decorte A., Van Damme-Lombaerts R., Fine R.N. Adherence to the immunosuppressive regimen in pediatric kidney transplant recipients: a systematic review. Pediatr Transplant 2010, 14:603-613.
60. Tong A., Howell M., Wong G., Webster A.C., Howard K., Craig J.C. The perspectives of kidney transplant recipients on medicine taking: a systematic review of qualitative studies. Nephrol Dial Transplant 2011, 26:344-354.
61. Jamieson N.J., Hanson C.S., Josephson M.A., et al. Motivations, challenges, and attitudes to self-management in kidney transplant transplant recipients: a systematic review of qualitative studies. Am J Kidney Dis 2016, 67:461-478.
62. Massey E.K., Tielen M., Laging M., et al. Discrepancies between beliefs and behavior: a prospective study into immunosuppressive medication adherence after kidney transplantation. Transplantation 2015, 99:375-378.
63. Patel R., Terasaki P.I. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969, 280:735-739.
64. Mahoney R.J., Taranto S., Edwards E. B-cell crossmatching and kidney allograft outcome in 9031 United States transplant recipients. Hum Immunol 2002, 63:324-335.
65. Fidler S., Swaminathan R., Lim W., et al. Peri-operative third party red blood cell transfusion in renal transplantation and the risk of antibody-mediated rejection and graft loss. Transpl Immunol 2013, 29:22-27.
66. Otten H.G., Verhaar M.C., Borst H.P., Hené R.J., van Zuilen A.D. Pretransplant donor-specific HLA Class-I and class-II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant 2012, 12:1618-1623.
67. Reinsmoen N.L., Lai C.H., Heidecke H., et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation 2010, 90:1473-1477.
68. Giral M., Foucher Y., Dufay A., et al. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss. Am J Transplant 2013, 13:2567-2576.
69. Dragun D., Catar R., Kusch A., Heidecke H., Philippe A. Non-HLA-antibodies targeting angiotensin type 1 receptor and antibody mediated rejection. Hum Immunol 2012, 73:1282-1286.
70. Loupy A., Lefaucheur C., Vernerey D., et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013, 369:1215-1226.
71. Ashoor I., Najafian N., Korin Y., et al. Standardization and cross validation of alloreactive IFNγ ELISPOT assays within the clinical trials in organ transplantation consortium. Am J Transplant 2013, 13:1871-1879.
72. Hricik D.E., Augustine J., Nickerson P., et al. Interferon gamma ELISPOT testing as a risk-stratifying biomarker for kidney transplant injury: results from the CTOT-01 multicenter study. Am J Transplant 2015, 15:3166-3173.
73. Bestard O., Crespo E., Stein M., et al. Cross-validation of IFN-γ elispot assay for measuring alloreactive memory/effector T cell responses in renal transplant recipients. Am J Transplant 2013, 13:1880-1890.
74. Dragun D., Catar R., Philippe A. Non-HLA antibodies in solid organ transplantation: recent concepts and clinical relevance. Curr Opin Organ Transpl 2013, 18:430-435.
75. Hricik D.E., Formica R.N., Nickerson P., et al. Adverse outcomes of tacrolimus withdrawal in immune-quiescent kidney transplant recipients. J Am Soc Nephrol 2015, 26:3114-3122.
76. Hirt-Minkowski P., Roth M., Hönger G., Amico P., Hopfer H., Schaub S. Soluble CD30 correlates with clinical but not subclinical renal allograft rejection. Transpl Int 2013, 26:75-83.
77. Pavlova Y., Viklicky O., Slatinska J., et al. Soluble CD30 and hepatocyte growth factor as predictive markers for antibody-medicated rejection of the kidney allograft. Transpl Immunol 2011, 25:72-76.
78. Hönger G., Fornaro I., Granado C., Tiercy J.M., Hösli I., Schaub S. Frequency and determinants of pregnancy-induced child-specific sensitization. Am J Transplant 2013, 13:746-753.
79. Higgins R., Lowe D., Daga S., et al. Pregnancy-induced HLA antibodies respond more vigorously after renal transplantation than antibodies induced by prior transplantation. Hum Immunol 2015, 76:546-552.
80. Abu Jawdeh B.G., Cuffy M.C., Alloway R.R., Shields A.R., Woodle E.S. Desensitization in kidney transplantation: review and future perspectives. Clin Transplant 2014, 28:494-507.
81. Cole E., Tinckam K.J. Densesensitization outomes: quantifying and questioning. Am J Transplant 2014, 14:1475-1476.
82. Orandi B.J., Garonzik-Wang J.M., Massie A.B., et al. Quantifying the risk of incompatible kidney transplantation: a multicenter study. Am J Transplant 2014, 14:1573-1580.
83. Gloor J.M., Winters J.L., Cornell L.D., et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010, 10:582-589.
84. Riella L.V., Safa K., Yagan J., et al. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch. Transplantation 2014, 97:1247-1252.
85. Vo A.A., Sinha A., Haas M., et al. Factors predicting risk for antibody-mediated rejection and graft loss in highly human leukocyte antigen sensitized patients transplanted after desensitization. Transplantation 2015, 99:1423-1430.
86. Crespo E., Lucia M., Cruzado J.M., et al. Pre-transplant donor-specific T-cell alloreactivity is strongly associated with early acute cellular rejection in kidney transplant recipients not receiving T-cell depleting induction therapy. PLoS One 2015, 10.
87. Foster B.J., Dahhou M., Zhang X., Platt R.W., Smith J.M., Hanley J.A. Impact of HLA mismatch at first kidney transplant on lifetime with graft function in young recipients. Am J Transplant 2014, 14:876-885.
88. Shin S., Kim Y.H., Choi B.H., et al. Long-term impact of human leukocyte antigen mismatches combined with expanded criteria donor on allograft outcomes in deceased donor kidney transplantation. Clin Transplant 2015, 29:44-51.
89. Sagedal S., Nordal K.P., Hartmann A., et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002, 2:850-856.
90. Ergbruegger U., Scheffner I., Mengel M., et al. Impact of CMV infection on acute rejection and long-term renal allograft function: a systematic analysis in patients with protocol biopsies and indicated biopsies. Nephrol Dial Transplant 2012, 27:435-443.
91. Erdbruegger U., Scheffner I., Mengel M., Schwarz A., Haller H., Gwinner W. Long-term impact of CMV infection on the allograft and on patient survival in renal transplant patients with protocol biopsies. Am J Physiol Renal Physiol 2015, 309:F925-F932.
92. Li L., Chaudhuri A., Weintraub L.A., et al. Subclinical cytomegalovirus and Epstein-Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation. Pediatr Transplant 2007, 11:187-195.
93. Schroth M., Rascher W., Rösch W.H., Dötsch J. Epstein-Barr virus triggered rejection after kidney allograft transplantation. J Pediatr Urol 2005, 1:359-360.
94. Hirsch H.H., Vincenti F., Friman S., et al. Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. Am J Transplant 2013, 13:136-145.
95. Manitpisitkul W., Drachenberg C., Ramos E., et al. Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: a case-control study. Transplantation 2009, 88:83-88.
96. Sawinski D., Forde K.A., Trofe-Clark J., et al. Persistent BK viremia does not increase intermediate-term graft loss but is associated with de novo donor-specific antibodies. J Am Soc Nephrol 2015, 26:966-975.
97. Debout A., Foucher Y., Trébern-Launay K., et al. Each additional hour of cold ischemia time significantly increases the risk of graft failure and mortality following renal transplantation. Kidney Int 2015, 87:343-349.
98. Doshi M.D., Garg N., Reese P.P., Parikh C.R. Recipient risk factors associated with delayed graft function: a paired kidney analysis. Transplantation 2011, 91:666-671.
99. Kayler L.K., Magliocca J., Zendejas I., Srinivas T.R., Schold J.D. Impact of cold ischemia time on graft survival among ECD transplant recipients: a paired kidney analysis. Am J Transplant 2011, 11:2647-2656.
100. van de Vliet J.A., Warlé M.C. The need to reduce cold ischemia time in kidney transplantation. Curr Opin Organ Transplant 2013, 18:174-178.
101. Mikhalski D., Wissing K.M., Ghisdal L., et al. Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression. Transplantation 2008, 85(7 Suppl.):S3-S9.
102. Salahudeen A.K., May W. Reduction in cold ischemia time of renal allografts in the United States over the last decade. Transplant Proc 2008, 40:1285-1289.
103. Simpkins C.E., Montgomery R.A., Hawxby A.M., et al. Cold ischemia time and allograft outcomes in live donor renal transplantation: is live donor organ transport feasible?. Am J Transplant 2007, 7:99-107.
104. Moers C., Smits J.M., Maathuis M.H., et al. Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med 2009, 360:7-19.
105. Watson C.J., Wells A.C., Roberts R.J., et al. Cold machine perfusion versus static cold storage of kidneys donated after cardiac death: a UK multicenter randomized controlled trial. Am J Transplant 2010, 10:1991-1999.
106. Kwiatkowski A., Wszoła M., Kosieradzki M., et al. The early and long term function and survival of kidney allografts stored before transplantation by hypothermic pulsatile perfusion. A prospective randomized study. Ann Transplant 2009, 14:14-17.
107. Yarlagadda S.G., Coca S.G., Formica R.N., Poggio E.D., Parikh C.R. Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis. Nephrol Dial Transplant 2009, 4:1039-1047.
108. Laftavi M.R., Sharma R., Feng L., Said M., Pankewycz O. Induction therapy in renal transplant recipients: a review. Immunol Invest 2014, 43:790-806.
109. Flechner S.M., Kobashigawa J., Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 2008, 22:1-15.
110. Pascual J. Steroid avoidance or withdrawal in kidney transplantation. Curr Opin Organ Transplant 2011, 16:600-605.
111. Jameson J.L., Longo D.L. Precision medicine-personalized, problematic, and promising. N Engl J Med 2015, 372:2229-2234.